Madison, Wisconsin headquartered Exact Sciences Corp.'s shares dropped 7.65%, closing Thursday's trading session at $13.64. The stock recorded a trading volume of 2.80 million shares, which was above its three months average volume of 2.62 million shares. Shares of the Company have advanced 47.78% since the start of this year. The stock is trading 8.41% above its 200-day moving average. Additionally, shares of Exact Sciences, which focuses on developing products for the early detection and prevention of various cancers, have a Relative Strength Index (RSI) of 32.66.
On November 18th, 2016, Exact Sciences announced that, in support of its continued growth plans, it granted restricted stock units covering a total of 47,704 shares of common stock to 40 recently hired non-executive employees. The restricted stock unit awards vest in four equal annual installments beginning on the first anniversary of the grant date. See our free and comprehensive research report on EXAS at:
On Thursday, shares in Santa Clara, California headquartered Agilent Technologies Inc. recorded a trading volume of 2.82 million shares, which was above their three months average volume of 2.04 million shares. The stock fell 1.75%, ending the day at $43.21. The Company's shares have advanced 4.18% on an YTD basis. The stock is trading below its 200-day moving average by 1.57%. Furthermore, shares of Agilent Technologies, which provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide, have an RSI of 38.13.
On November 10th, 2016, research firm Leerink Partners resumed its 'Outperform' rating on the Company's stock.
On November 30th, 2016, Agilent Technologies announced the opening of a new $14.7 million, 53,000 square-foot Technology Center in Folsom, California. The new building, which is adjacent to Agilent's existing facility at 91 Blue Ravine Road, will house approximately 60 additional staff. The new facility includes a state-of-the-art customer applications laboratory and collaboration space, as well as facilities for providing the company's groundbreaking scientific consumables and supplies. Agilent Technologies solutions are used by laboratories worldwide, involved in many areas from cancer research to testing the quality and safety of food, water, and pharmaceuticals. A free research report PDF is just a click away at:
Chicago, Illinois headquartered Hill-Rom Holdings Inc.'s stock finished the day 0.79% lower at $52.92 with a total trading volume of 593,630 shares. The Company's shares have gained 11.21% on an YTD basis. The stock is trading below its 200-day moving average by 0.35%. Additionally, shares of Hill-Rom, which operates as a medical technology company worldwide, have an RSI of 37.11.
On November 22nd, 2016, Hill-Rom announced its Welch Allyn subsidiary's entrance into the connected home monitoring market with its new Welch Allyn Home™ Hypertension Program. The company stated that the Welch Allyn Home™ Hypertension Program will enable patients to monitor their health outside the physician office using the clinically trusted Welch Allyn Home Blood Pressure Monitor. Patients can seamlessly sync their monitor to a smartphone app that allows them to engage in their progress towards healthy BP goals. For practitioners, this data will transmit to the free Clinical Portal, which provides practitioner visibility to patient compliance against treatment recommendations and an organized view of accurate information. Sign up for your complimentary report on HRC at:
Shares in Milford, Massachusetts-based Waters Corp. ended yesterday's session 0.64% lower at $133.71 with a total trading volume of 553,493 shares. The stock is trading 6.14% below its 200-day moving average. Shares of the Company, which operates as an analytical instrument manufacturer in the US and internationally, have an RSI of 34.94.
On November 10th, 2016, research firm Leerink Partners resumed its 'Outperform' rating on the Company's stock, issuing a target price of $163 per share.
On November 30th, 2016, a consortium of leading research centers from six different countries launched the International Phenome Centre Network (IPCN) at the 2016 World Innovation Summit for Health in Doha, Qatar. Through its commitment to harmonized metabolic phenotyping methods, the IPCN will tackle some of the most pressing global health challenges, such as autism, cancer, diabetes, dementia and obesity. Supporting the network with its chromatography and mass spectrometry technologies and expertise, Waters Corp. is a founding corporate partner of the IPCN. Register for free on Stock-Callers.com and download the latest research report on WAT at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA